Blankinship & Foster’s Summit Therapeutics SMMT Stock Holding History

Blankinship & Foster’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Hold	12,777	–	–	0.04%	79
2026 Q1	$242K	Hold	12,777	–	–	0.05%	69
2025 Q4	$223K	Hold	12,777	–	–	0.05%	74
2025 Q3	$264K	Hold	12,777	–	–	0.06%	64
2025 Q2	$272K	Hold	12,777	–	–	0.06%	63
2025 Q1	$246K	Hold	12,777	–	–	0.06%	61
2024 Q4	$228K	Hold	12,777	–	–	0.06%	64
2024 Q3	$280K	Hold	12,777	–	–	0.07%	56
2024 Q2	$99.7K	Hold	12,777	–	–	0.03%	71
2024 Q1	$52.9K	Hold	12,777	–	–	0.01%	67
2023 Q4	$33.3K	Hold	12,777	–	–	0.01%	68
2023 Q3	$23.9K	Hold	12,777	–	–	0.01%	57
2023 Q2	$32.1K	Buy	+12,777	New	+$23.3K	0.01%	55

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Blankinship & Foster's SMMT Position: Q2 2026 in Review

Blankinship & Foster held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 12,777 shares worth $186K. The position accounts for 0.04% of the portfolio, ranked #79.

Blankinship & Foster first reported a position in SMMT in Q2 2023 and has held it in 13 quarters since. The position peaked at $280K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Blankinship & Foster held 12,777 shares of Summit Therapeutics worth $186K as of Q2 2026.
Blankinship & Foster left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up 0.04% of Blankinship & Foster's portfolio in Q2 2026, its #79 holding.
Blankinship & Foster first reported a position in Summit Therapeutics in Q2 2023 and has held it in 13 quarters since.
Blankinship & Foster's Summit Therapeutics position peaked at $280K in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Blankinship & Foster's 13F filing for Q2 2026, filed 31 Jul 2026.